You are here:Home-Inhibitors & Agonists-Apoptosis-RIP kinase

Request The Product List ofRIP kinase RIP kinase

Cat. No. Product Name CAS No. Information
PC-36133

cRIPGBM

cRIPGBM (RIPGBM derivative cRIPGBM, RIPGBM-18) is a metabolite of RIPGBM induces apoptosis in GBM CSCs (EC50=68 nM in GBM 1 cells) by interacting with RIPK2 (Kd=2.3 uM); induces caspase 1-dependent apoptosis, reduces the formation of a prosurvival RIPK2/TAK1 complex and increases the formation of a proapoptotic RIPK2/caspase 1 complex.

PC-36132

RIPGBM

355406-76-7

RIPGBM is a cell type-selective, small molecule inducer of apoptosis in GBM cancer stem cells (CSCs) with EC50 of 220 nM (GBM 1 cells); RIPGBM is converted to an apoptosis-inducing derivative (cRIPGBM/RIPGBM-18) selectively in GBM CSCs; cRIPGBM induces apoptosis in GBM CSCs by interacting with RIPK2; significantly suppress tumor formation in vivo in orthotopic intracranial GBM CSC tumor xenograft mouse model.

PC-35793

GSK547

2226735-55-1

GSK547 (RIP1i, GSK 547) is a highly selective and potent inhibitor of RIP1 kinase that robustly targets RIP1 in vivo; exhibited a 400-fold improvement in mouse pharmacokinetic oral exposure compared with GSK'963; reprogrammed TAMs toward an MHCIIhiTNFα+IFNγ+ immunogenic phenotype in a STAT1-dependent manner. RIP1 inhibition in TAMs resulted in cytotoxic T cell activation and T helper cell differentiation toward a mixed Th1/Th17 phenotype, leading to tumor immunity in mice and in organotypic models of human Pancreatic ductal adenocarcinoma (PDA).

PC-35429

CSLP43

2244988-80-3

CSLP43 (RIPK2 inhibitor CSLP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling; exhibits inhibition of TNF release from RAW264.7 cells with EC50 of 1.2 nM, inhibits NF-κB reporter activity with IC50 of 1.34 nM; antagonizes NOD2 signaling by interfering with the XIAP-RIPK2 interaction, selectively inhibits NOD responses in cells (HEKBlue NOD2 IC50=1.3 nM) and displays potent activity in vivo, does not attenuates the TNF release following an unrelated pro-inflammatory stimulation mediated through TLR4 activation by LPS at 1 uM.

PC-35428

CSLP37

2244984-64-1

CSLP37 (RIPK2 inhibitor CSLP37) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 16.3 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling; exhibits inhibition of TNF release from RAW264.7 cells with EC50 of 12.6 nM, inhibits NF-κB reporter activity with IC50 of 22.5 nM; antagonizes NOD2 signaling by interfering with the XIAP-RIPK2 interaction, selectively inhibits NOD responses in cells (HEKBlue NOD2 IC50=26.3 nM) and displays potent activity in vivo, does not attenuates the TNF release following an unrelated pro-inflammatory stimulation mediated through TLR4 activation by LPS at 1 uM.

PC-63258

RIPK2 inhibitor 1

1290490-78-6

RIPK2 inhibitor 1 is a novel potent, selective RIPK2 inhibitor with IC50 of 5-10 nM; potently inhibits the proliferation of cancer cells by > 70% and also inhibits NF-κB activity.

PC-62661

GSK-872

1346546-69-7

GSK-872 (GSK'872) is a potent and selective RIPK3 (receptor-interacting protein kinase-3) inhibitor; interferes with receptor-mediated endocytosis, entry of HIV, and synaptic vesicle recycling; attenuates rat nucleus pulposus (NP) cells death.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com